Nucleic Acid Vector Tablets
Patent No. EP3621596 (titled "Nucleic Acid Vector Tablets") was filed by Centre National DE LA Recherche Scientifique on May 9, 2018. The application was issued on Feb 23, 2022.
Patent Summary
Method for manufacturing tablets containing nucleic acid vectors for oral, vaginal, rectal, sublingual or transmucosal administration. The method involves drying a complex of nucleic acid and lipid particles containing cationic lipids, followed by compression into tablets. The lipid particles can be liposomes or micelles. The drying step can be lyophilization. The tablets provide a convenient oral dosage form for nucleic acids that avoids the limitations of injectable vectors.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3621596
- Application Number
- EP18738197A
- Filing Date
- May 9, 2018
- Status
- Opposition Rejected
- Feb 28, 2025
- Publication Date
- Feb 23, 2022
- External Links
- Slate, Register , Google Patents